Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
|Webinars|December 20, 2021
Success in Value-Based Contracting—Using Evidence, Technology, and Data to Improve Outcomes and Eliminate Low-Value Care, Part 3
Experts from Optum, WellMed, and Reliant discuss strategies for bringing value-based payment into specialty care through the use of education and analytics.
Advertisement
In the latest Matters in Managed Care webinar, experts discussed how to improve outcomes and eliminate low-value care. They defined actions and practices that constitute wasted and harmful care, described how to rapidly translate high-quality evidence-based medicine into daily practice, recognized how to leverage technology, and more.
Ken Cohen, MD, FACP, senior medical director and executive director, clinical research national senior medicaldirector, Optum Care, moderated the panel with:
- Troy Comstock, MD, regional medical director, Florida WellMed Medical Management
- Dan Murrey, MD, MPP, chief medical officer, surgical care associates; president, OptumCare Specialty Practices
- Thad Schilling, MD, chief medical officer, Reliant Medical Group
In segment 3, they discussed using analytics to control drug spend and optimize care.
Advertisement
Related to this article
The Franklin County death is under state review as Pennsylvania's measles outbreak passed 1100 cases and 219 hospitalizations.
Among 4378 Spanish registry patients, dyshidrotic eczema was less tied to occupation than other hand eczema.
New non-CF bronchiectasis in Medicare is tied to high health care use and $8998 PPPM FFS spending; prevalence is highest in older women.
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
NPC researchers examined questions about how these policies could affect patients, pharmacies, and providers.
The expanded indication rests on evidence extrapolated from carcinoma in situ, a new FDA approach to closely related forms of bladder cancer.
A historical review traces Sjögren disease from its early descriptions to the use of salivary gland ultrasound in diagnosis.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
3
MedHaul Closes Care Gaps With Single Stop for Getting Patients to Appointments
4
FDA Approves First Treatment for BCG-Unresponsive Bladder Cancer
5